Release this Report to Investors

Via Email

Via Text


If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us

We are excited to present BG Medicine, Inc. (OTC: BGMD).

Full DD Report for BGMD

Recent News from (OTC: BGMD)

BG Medicine withdraws 510(k) app for new indication of Galectin-3 Test
BG Medicine (NASDAQ: BGMD ) withdraws its 510(k) submission with the FDA, filed on March 31, seeking clearance for the use of its Galectin-3 Test as an aid in the assessment of the near term risk of fatal cardiovascular events in older adults who have no prior history of cardiovascular dis...
Source: SeekingAlpha
Date: December, 23 2015 08:21
BG Medicine Withdraws 510(k) Premarket Notification for Proposed Additional Indication for the BGM Galectin-3® Test
WALTHAM, Mass., Dec. 23, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD)  today announced that it has submitted to the FDA a notice of withdrawal of its 510(k) premarket notification filing with the US Food and Drug Administration (“FDA”) that was submitted in ord...
Source: GlobeNewswire
Date: December, 23 2015 07:50
BG Medicine: Nearing The Finish Line
Introduction When BG Medicine (BGMD) went public nearly a half decade ago, it did so with much fanfare and hope for the future of its FDA approved Galectin-3 test to predict heart failure in individuals already diagnosed with the disease. This clearance - which was only ever intended to be...
Source: SeekingAlpha
Date: December, 03 2015 05:45
BG Medicine and Abbott revise galectin-3 agreement to improve penetration of reference labs
BG Medicine (NASDAQ: BGMD ) amends its License and Distribution Agreement with Abbott Diagnostics (NYSE: ABT ) lowering the fees paid to BG for galectin-3 tests sold by Abbott to reference laboratories. The specific amount of the reduction is undisclosed. The original fees will remain un...
Source: SeekingAlpha
Date: November, 30 2015 08:43
License and Distribution Agreement Amended
WALTHAM, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc.  (OTCQB:BGMD), the developer of the BGM Galectin-3 ® Test, today announced an amendment to its license and distribution agreement for Galectin-3. Amendment to License and Distribution Agreement In suppor...
Source: GlobeNewswire
Date: November, 30 2015 07:39
BG Medicine's (BGMD) CEO Paul Sohmer on Business Update Call
BG Medicine, Inc. (BGMD) Business Update Call November 17, 2015, 09:30 AM ET Executives Paul Sohmer - President and CEO Steve Hall - CFO Aram Adourian - Chief Scientific Officer Analysts Presentation Operator Good day, ladies and gentlemen, and welcome to the BG Med...
Source: SeekingAlpha
Date: November, 17 2015 14:12
BG Medicine Reports Third Quarter 2015 Financial Results
WALTHAM, Mass., Nov. 17, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD), the developer of the BGM Galectin-3 ® Test, today reported financial results for the three and nine months ended September 30, 2015. “Our operating results in the third quarter of 2015 reflec...
Source: GlobeNewswire
Date: November, 17 2015 07:50
BG Medicine reports Q3 results
BG Medicine (NASDAQ: BGMD ): Q3 EPS of -$0.27 More news on: BG Medicine, Inc., Earnings news and commentary, Healthcare stocks news Read more ...
Source: SeekingAlpha
Date: November, 17 2015 07:17
BG Medicine Announces Business Update Conference Call Information
WALTHAM, Mass., Nov. 11, 2015 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (OTCQB:BGMD) today announced that the company will host a business update conference call and webcast on Tuesday, November 17, 2015, beginning at 8:30 a.m. Eastern Time. Conferenc e Call Details The conference call ...
Source: GlobeNewswire
Date: November, 11 2015 16:30
BG Medicine Due Diligence Report: Quietly Making Headway - Broad Street Alerts
NEW YORK, NY / ACCESSWIRE / November 5, 2015 / BG Medicine, Inc. (OTCQB: BGMD) the developer of the BGM Galectin-3 recently announced that trading in the Company's common stock will be suspended on NASDAQ effective with the open of business on Wednesday, September 16, 2015, due to the Compan...
Date: November, 05 2015 08:33


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report.

About BG Medicine, Inc. (OTC: BGMD)

Logo for BG Medicine, Inc. (OTC: BGMD)

BG Medicine, Inc. is a commercial stage company that is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders.


Contact Information



Current Management

  • Paul Sohmer / President
  • Stephen Hall / CFO, EVP
  • Aram Adourian / Chief Scientific Officer
  • Noubar Afeyan /
  • James F. O Connor / James F. O Connor, age , has over forty years of substantive business experience covering all aspects of finance, operations, strategy and corporate development. Since , Mr. O Connor has been the principal Managing Director of The Chartwell Company, a merchant and investment banking firm. Mr. O Connor is a certified public accountant. Some of Mr. O Connor s previous directorships include: SPS Technologies , which was sold to Precision Cast Products in Color Kinetics , which was sold to Phillips Lighting Products in PC Cox Holding Ltd. and Caritas Christi Health Care System , which was sold to Cerberus Capital in . Mr. O Connor received a B.S. from Boston College and was a Rotary International Foundation Fellow at the Swiss School of Economics. Our Board concluded that Mr. O Connor should serve as a director and our Audit Committee Chairman because Mr. O Connor has extensive experience in corporate finance, accounting, operations, strategy, mergers amp acquisitions, as well as experience working on the boards of directors of public, private and nonforprofit companies.
  • Stelios Papadopoulos /
  • Paul Sohmer /
  • Harry Wilcox /

Current Share Structure

  • Market Cap: $739,162 - 03/09/2018
  • Authorized: 100,000,000 - 09/01/2015
  • Issue and Outstanding: 11,319,475 - 03/15/2016
  • Float: 9,394,980 - 09/15/2015


Recent Filings from (OTC: BGMD)

Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: June, 23 2016
Termination of registration under Section 12(b) or suspension of duty to file reports
Filing Type: 15-12BFiling Source: edgar
Filing Date: May, 05 2016
Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 04 2016
Amendment to a previously filed 10-K
Filing Type: 10-K/AFiling Source: edgar
Filing Date: April, 29 2016
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: April, 04 2016
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 04 2016
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 04 2016
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 31 2016
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: March, 31 2016
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 31 2016


Daily Technical Chart for (OTC: BGMD)

Daily Technical Chart for (OTC: BGMD)

Stay tuned for daily updates and more on (OTC: BGMD)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: BGMD)

Do your DD and if you choose, be ready to go!


The Research: All source information contained in this email is from the public sources mentioned below.



Thank you

The Subway Trader



Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in BGMD is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $0 from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of BGMD and does not buy, sell, or trade any shares of BGMD. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: